Looking at Long-term Results, New Opportunities With CAR T-Cell Therapies
Source : https://www.ajmc.com/view/looking-at-long-term-results-new-opportunities-with-car-t-cell-therapies
Schuster, director of the Lymphoma Program at the Abramson Cancer Center, University of Pennsylvania, was the principal investigator for the trial that led to the approval of tisagenlecleucel, or tisa-cel...
-
Mark Fesler4yrNice overview outlining the sobering fact that still 2/3rds of car T cell treated patients relapse or don’t respond, which reflects a persistent great unmet need
Hepatitis B virus antibody status provides new insights in diffuse large B-Cell lymphoma
Source : https://doi.org/10.1080/10428194.2021.1891233
PDF download + Online access 48 hours access to article PDF & online version Article PDF can be downloaded Article PDF can be printed USD 57.00 Issue Purchase 30 days...
Paper: Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma
Oral and Poster Abstracts Oral 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)-Results from Retrospective/Observational Studies: Biomarkers and Prognostication in Aggressive B-Cell Non-Hodgkin Lymphomas Adult, Diseases,...
-
Mark Fesler4yrThis important article advances the knowledge of circulating tDna in DLBCL and like many other articles, suggests the prognostic value of this assessment. I’m not aware of a commercially Show More
The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy
Source : https://doi.org/10.1080/10428194.2020.1869965
Abstract We addressed the prognostic impact of cell-of-origin (COO), MYC and Bcl-2 overexpression as well as isolated MYC rearrangement among 111 patients with limited stage diffuse large B-cell lymphoma (DLBCL)...
-
Mark Fesler4yrThere is a paucity of data on the prognostic and predictive value of subtyping limited stage DLBCL. Unfortunately this was not a homogeneously treated cohort which makes definitive conclusions on Show More
Application of high-throughput gene sequencing in lymphoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33493455/
As a malignant tumor originating from the lymphoid hematopoietic tissues, lymphoma has an increased incidence in recent years and has ranked among the top ten malignant tumors in the world....
-
Mark Fesler4yrThe only clinically relevant mutations in terms of predictive value lymphomas presently are p53 in mantle cell /CLL and myd88 in waldenstrom. In the case of mantle cell/CLL, we Show More